SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity of $250.11M in Q1 FY2026
Q1 FY2026 total equity was $250.11M.
Context
- Total equity amounted to 96.8% of total assets at the end of Q1 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- (98.84M) USD
- Year-over-year change
- —
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (98.84M) | — |
Total Equity vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Total equity amounts to 96.8% of total assets for SGP, versus a peer median of 78.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $21.73B USD | -1.5% | +3.8% | 69.3% | |
| Jun 2026 | $6.44B USD | -1.0% | -2.8% | 46.5% | |
| Jun 2026 | $682.49M USD | -10.8% | +7.4% | 74.1% | |
| Mar 2026 | $581.57M USD | +118.7% | +164.5% | 79.4% | |
| Apr 2026 | $352.37M USD | +0.7% | +0.8% | 78.1% | |
| Mar 2026 | $267.3M USD | -4.3% | +45.3% | 87.9% | |
SGPSpyGlass Pharma, Inc. Common Stock | Mar 2026 | $250.11M USD | — | — | 96.8% |
| Mar 2026 | $230.47M USD | -22.8% | +47.0% | 80.0% | |
| Mar 2026 | CHF 196.06M CHF | +20.6% | — | 80.6% | |
| Mar 2026 | $53.9M USD | -30.6% | -26.4% | 49.1% | |
| Peer median (excluding SGP) | — | -1.5% | +5.6% | 78.1% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.